Detailed Information on Publication Record
2023
Level I axillary dissection in patients with breast cancer and tumor-involved sentinel lymph node after NAC is not sufficient for adequate nodal staging
ŽATECKÝ, Jan, Oldřich COUFAL, Miloš HOLÁNEK, Otakar KUBALA, Markéta KEPIČOVÁ et. al.Basic information
Original name
Level I axillary dissection in patients with breast cancer and tumor-involved sentinel lymph node after NAC is not sufficient for adequate nodal staging
Authors
ŽATECKÝ, Jan (203 Czech Republic, guarantor, belonging to the institution), Oldřich COUFAL, Miloš HOLÁNEK, Otakar KUBALA, Markéta KEPIČOVÁ, Jiří GATĚK, Milan LERCH and Matúš PETEJA (203 Czech Republic, belonging to the institution)
Edition
Turkish Journal of Surgery, 2023, 2564-6850
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30212 Surgery
Country of publisher
Turkey
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
RIV identification code
RIV/47813059:19510/23:A0000464
Organization unit
Faculty of Public Policies in Opava
Keywords in English
Breast cancer; sentinel lymph node biopsy; neoadjuvant chemotherapy; axillary dissection; level I axillary dissection
Tags
International impact, Reviewed
Změněno: 25/3/2024 13:59, Ing. Lucie Chmelařová
Abstract
V originále
Objective: The purpose of the study was to investigate the oncological sufficiency of level I axillary dissection for adequate histological nodal staging (ypN) in patients with breast cancer and tumor-involved sentinel lymph node (SLN) after neoadjuvant chemotherapy (NAC). Material and Methods: A prospective multicentre pilot study took place from 01.01.2018 to 30.11.2020 in three mammary centres in the Czech Republic in patients with breast cancer after NAC (NCT03556397). Patients in the cohort with positive histological frozen section of SLN were indicated to separate axillary dissection of levels I and II. Results: Sixty-one patients with breast cancer after NAC were included in the study according to inclusion and exclusion criteria. Twelve patients with breast cancer and tumour involved SLN after NAC were further included in the analysis. Two (16.7%) patients had positive non-sentinel lymph nodes in level I only, one (8.3%) patient had positive lymph nodes in level II only, and seven (58.3%) patients had positive lymph nodes in both levels. Level I axillary dissection in a patient with tumour involved SLN after NAC would have resulted in understaging in five (41.7%) patients, mostly ypN1 instead of ypN2. Conclusion: According to our pilot result, level I axillary dissection is not sufficient in terms of adequate histological nodal staging in breast cancer patients after NAC, and level II axillary dissection should not be omitted.